Osteoporosis - Pipeline Review, H1 2012

Global Markets Direct, February 2012, Pages: 238

Osteoporosis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Osteoporosis - Pipeline Review, H1 2012', provides an overview of the Osteoporosis therapeutic pipeline. This report provides information on the therapeutic development for Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoporosis. 'Osteoporosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Osteoporosis.
- A review of the Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Osteoporosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Osteoporosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Osteoporosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Osteoporosis Therapeutic Products under Development, Key Players in Osteoporosis Therapeutics, Osteoporosis Pipeline Overview, Osteoporosis Pipeline, Osteoporosis Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Osteoporosis Overview
Therapeutics Development
An Overview of Pipeline Products for Osteoporosis
Osteoporosis Therapeutics under Development by Companies
Osteoporosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Osteoporosis Therapeutics – Products under Development by Companies
Osteoporosis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Osteoporosis Therapeutics Development
Amgen Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co., Inc.
CardioVascular BioTherapeutics, Inc.
Teijin Pharma Limited
Novartis AG
Chiesi Farmaceutici SpA
Chugai Pharmaceutical Co. Ltd
Genta Incorporated
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Zydus Cadila Healthcare Limited
TransPharma Medical Ltd.
Zelos Therapeutics, Inc.
Geron Corporation
Zosano Pharma, Inc.
Bone Medical Limited
FAES Farma SA
Enzo Biochem, Inc.
Medivir AB
Calzada Limited
Novogen Limited
NPS Pharmaceuticals, Inc.
Osteologix, Inc.
Cosmo Pharmaceuticals S.p.A
Unigene Laboratories, Inc.
Dongwha Pharm Co., Ltd.
PhytoHealth Corporation
SCOLR Pharma, Inc.
Galapagos NV
Oscotec Inc.
Merrion Pharmaceuticals Plc
Acceleron Pharma, Inc.
Amura Holdings Ltd.
Affectis Pharmaceuticals AG
IMMD Inc.
Alethia Biotherapeutics Inc.
Pantarhei Bioscience BV
Zealand Pharma A/S
EffRx, Inc.
Radius Health, Inc.
USV Limited.
Ausio Pharmaceuticals, LLC
Osteoporosis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Xgeva - Drug Profile
Xgeva - Drug Profile
Odanacatib - Drug Profile
G4544 - Drug Profile
Sotatercept - Drug Profile
PREOS - Drug Profile
RG484 - Drug Profile
EX101 - Drug Profile
Estetrol - Drug Profile
Viviant - Drug Profile
Osteoblasts - Drug Profile
CVBT-141G - Drug Profile
NB S101 - Drug Profile
NV-07a - Drug Profile
AOD9604 - Drug Profile
ZT-034 Intranasal - Drug Profile
ZP2307 - Drug Profile
AUS-131 - Drug Profile
IMD-0560 - Drug Profile
MIV-710 - Drug Profile
MIV-711 - Drug Profile
DW-1350 - Drug Profile
Capsitonin - Drug Profile
Antibody Program For Bone Disorders - Drug Profile
Fosamax - Drug Profile
Calcium Carbonate + Vitamin D - Drug Profile
Risedronate - Drug Profile
Alendronate - Drug Profile
Risedronate - Drug Profile
Alendronate - Drug Profile
Osteoporosis Drug - Drug Profile
Gu-Sui-Bu - Drug Profile
Preotact - Drug Profile
BXL093 - Drug Profile
PHN031 - Drug Profile
Preotact + Boniva - Drug Profile
ONO-5334 - Drug Profile
ONO-5334 - Drug Profile
CHF4227 - Drug Profile
Teriparatide + Alendronate - Drug Profile
CaPTHymone - Drug Profile
Zoledronate - Drug Profile
ZP-PTH - Drug Profile
Zosano PTH - Drug Profile
Almerol - Drug Profile
Fosamax - Drug Profile
Risedronate - Drug Profile
Zoledronic Acid - Drug Profile
Fosamax - Drug Profile
Cyclophosphamide + Allogeneic stem cell transplantation - Drug Profile
Fosamax - Drug Profile
Testosterone + Somatropin - Drug Profile
Zometa + Calcium gluconate + Cholecalciferol - Drug Profile
Zoledronic Acid - Drug Profile
Zoledronate - Drug Profile
hPTH-(1-34) - Drug Profile
hPTH-(1-34) + Alendronate - Drug Profile
Nerixia - Drug Profile
BA058 - Drug Profile
BA058 - Drug Profile
Alendronate or Risedronate + Bone Densitometry - Drug Profile
Strontium Ranelate + Vitamin D3 - Drug Profile
Cyclophosphamide + Fludarabine + Antithymocyte Globulin + Total Body Irradiation + Stem Cell Transplantation - Drug Profile
Cyclophosphamide + Fludarabine + Thymoglubulin + Stem Cell Transplantation - Drug Profile
Fludarabine + Busulfan + Alemtuzumab + Allogeneic Stem Cell Transplantation - Drug Profile
Cyclosporin + Methotrexate + stemcell transplantation - Drug Profile
Parathyroid hormone + Alendronate - Drug Profile
Alendronate - Drug Profile
Oral PTH - Drug Profile
zoledronate - Drug Profile
Drug For Osteoporosis - Drug Profile
Reclast - Drug Profile
Teriparatide - Drug Profile
LY2541546 - Drug Profile
AB-25E9 - Drug Profile
GTH-42J - Drug Profile
AM-3701 - Drug Profile
ZYPH0907 - Drug Profile
Hematopoietic Stem Cell Transplantation - Drug Profile
BN005 - Drug Profile
BN008 - Drug Profile
Teriperatide Injection - Drug Profile
Prasterone + Premarin + Aviane - Drug Profile
ViaDor-hPTH (1-34) - Drug Profile
RAD 140 - Drug Profile
Antiosteoporotic - Drug Profile
BPS804 - Drug Profile
PF-04840082 - Drug Profile
NaQuinate - Drug Profile
AFC-5278 - Drug Profile
Actonel - Drug Profile
OCT-1547 - Drug Profile
OCT-SG815 - Drug Profile
ODS-656 - Drug Profile
Wnt Stimulator - Drug Profile
PYK2 Inhibitor - Drug Profile
ALK 4/7 Inhibitor - Drug Profile
Osteoporosis Therapeutics – Drug Profile Updates
Osteoporosis Therapeutics – Discontinued Products
Osteoporosis Therapeutics - Dormant Products
Osteoporosis – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Osteoporosis, H1 2012
Products under Development for Osteoporosis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Amgen Inc., H1 2012
Eli Lilly and Company, H1 2012
GlaxoSmithKline plc, H1 2012
Merck & Co., Inc., H1 2012
CardioVascular BioTherapeutics, Inc., H1 2012
Teijin Pharma Limited, H1 2012
Novartis AG, H1 2012
Chiesi Farmaceutici SpA, H1 2012
Chugai Pharmaceutical Co. Ltd, H1 2012
Genta Incorporated, H1 2012
Ono Pharmaceutical Co., Ltd., H1 2012
Pfizer Inc., H1 2012
Zydus Cadila Healthcare Limited, H1 2012
TransPharma Medical Ltd., H1 2012
Zelos Therapeutics, Inc., H1 2012
Geron Corporation, H1 2012
Zosano Pharma, Inc., H1 2012
Bone Medical Limited, H1 2012
FAES Farma SA, H1 2012
Enzo Biochem, Inc., H1 2012
Medivir AB, H1 2012
Calzada Limited, H1 2012
Novogen Limited, H1 2012
NPS Pharmaceuticals, Inc., H1 2012
Osteologix, Inc., H1 2012
Cosmo Pharmaceuticals S.p.A, H1 2012
Unigene Laboratories, Inc., H1 2012
Dongwha Pharm Co., Ltd., H1 2012
PhytoHealth Corporation, H1 2012
SCOLR Pharma, Inc., H1 2012
Galapagos NV, H1 2012
Oscotec Inc., H1 2012
Merrion Pharmaceuticals Plc, H1 2012
Acceleron Pharma, Inc., H1 2012
Amura Holdings Ltd., H1 2012
Affectis Pharmaceuticals AG, H1 2012
IMMD Inc., H1 2012
Alethia Biotherapeutics Inc., H1 2012
Pantarhei Bioscience BV, H1 2012
Zealand Pharma A/S, H1 2012
EffRx, Inc., H1 2012
Radius Health, Inc., H1 2012
USV Limited., H1 2012
Ausio Pharmaceuticals, LLC, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Osteoporosis Therapeutics – Drug Profile Updates
Osteoporosis Therapeutics – Discontinued Products
Osteoporosis Therapeutics – Discontinued Products (Contd..1)
Osteoporosis Therapeutics – Dormant Products
Osteoporosis Therapeutics – Dormant Products (Contd..1)
Osteoporosis Therapeutics – Dormant Products (Contd..2)
Osteoporosis Therapeutics – Dormant Products (Contd..3)
Osteoporosis Therapeutics – Dormant Products (Contd..4)
Osteoporosis Therapeutics – Dormant Products (Contd..5)

List of Figures
Number of Products under Development for Osteoporosis, H1 2012
Products under Development for Osteoporosis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Alzheimer's Disease – Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Fungal Infections – Pipeline Review, H1 2013
• HIV-1 Infection – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Major Depressive Disorder – Pipeline Review, H1 2013
• Bipolar Disorder (Manic Depression) – Pipeline Review, H1 2013
• Erectile Dysfunction – Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013